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REVIEW
Ibogaine and addiction in the animal model, a systematic
review and meta-analysis
M Belgers1,2,3, M Leenaars4, JR Homberg5, M Ritskes-Hoitinga4, AFA Schellekens2,3 and CR Hooijmans4
Ibogaine is a naturally occurring substance which has been increasingly used in the lay-scene to reduce craving and relapse in
patients with substance use disorders (SUDs). Although human clinical trials on the safety and efﬁcacy of ibogaine are lacking,
animal studies do support the efﬁcacy of ibogaine. In this systematic review and meta-analysis (MA), we summarise these animal
ﬁndings, addressing three questions: (1) does ibogaine reduce addictive behaviour in animal models of SUDs?; (2) what are the
toxic effects of ibogaine on motor functioning, cerebellum and heart rhythm?; (3) what are neuropharmacological working
mechanisms of ibogaine treatment in animal models of SUDs? MA of 27 studies showed that ibogaine reduced drug self-
administration, particularly during the ﬁrst 24 h after administration. Ibogaine had no effect on drug-induced conditioned place
preference. Ibogaine administration resulted in motor impairment in the ﬁrst 24 h after supplementation, and cerebral cell loss even
weeks after administration. Data on ibogaines effect on cardiac rhythm, as well as on its neuropharmacological working
mechanisms are limited. Our results warrant further studies into the clinical efﬁcacy of ibogaine in SUD patients in reducing craving
and substance use, but close monitoring of the patients is recommended because of the possible toxic effects. In addition, more
work is needed to unravel the neuropharmacological working mechanisms of ibogaine and to investigate its effects on heart
rhythm.
Translational Psychiatry (2016) 6, e826; doi:10.1038/tp.2016.71; published online 31 May 2016
INTRODUCTION
Substance use disorders (SUDs) account for a large share of the total
global burden of disease. Nearly 5% of all disability-adjusted life
years and 4% of overall mortality appear to be attributed to SUDs.1–3
SUDs are often characterized by chronicity and frequent relapse.
Despite treatment, 5-year relapse rates are as high as 70% for alcohol
dependence, 78% for cocaine dependence and 97% for opioid
dependence.4–6 Moreover, for opioid dependence, pharmacological
treatment mainly consists of harm reduction strategies, using opioid
substitution with opioid agonists7,8 and for cocaine dependence no
effective pharmacological treatment is available at all.9
As a consequence, new and more effective pharmacological
treatment modalities are needed. Several new treatments have
been investigated, with some more promising than others. One
promising compound is ibogaine, a naturally occurring substance
in an African shrub. This compound has been claimed to reduce
craving and relapse rates in patients with SUDs.10 Indeed, case
reports mention a reduction of withdrawal symptoms and relapse
after a single dose of ibogaine with a sustainability of this effect of
several months.11 Ibogaine has increasingly been used for this
purpose over the last decades, mainly in a lay-scene.12,13 However,
human clinical trials on the safety and efﬁcacy of ibogaine for
patients with SUDs are lacking.
Various animal studies seem to support the claim that ibogaine
could have anti-addictive effects. The use of even a single dose of
ibogaine appears to be effective in a variety of well-validated
animal models for SUDs.10,14 Other animal studies describe
neurobiological effects of ibogaine.15,16 These ﬁndings ﬁt well
with current insight into the pathophysiology of SUDs and its
pharmacological targets, assigning a dominant role to dysfunction
in the brain dopamine, serotonin and stress systems in SUDs.17,18
However, a major concern in the use of ibogaine is its potential
cerebellar and cardiac toxicity, which has been described in both
animal studies and human case reports.19–21
In order to create an overview of possible therapeutic and
adverse effects, and further our understanding of the neurophar-
macological working mechanism of ibogaine, we conducted a
systematic review (SR) and meta-analysis (MA) of animal studies
regarding this topic. We propose that SR and MA of animal studies
will increase our insight into the possible therapeutic effects,
toxicity and potential mechanism of action of ibogaine. In addition,
the results of this review might guide the design of future clinical
trials.22 Therefore, three research questions will be addressed: (1)
Does ibogaine reduce addictive behaviour in animal models of
SUDs?; (2) Does ibogaine supplementation to animals cause
adverse toxic effects?; and (3) Does ibogaine inﬂuence addiction-
related neurobiological response in animal models of SUDs?
MATERIALS AND METHODS
The present review was based on published results of the
therapeutic, toxic and neurobiological effects of ibogaine in
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animal studies. The inclusion criteria and methods of analysis were
speciﬁed in advance and documented in a protocol and published
on the SYRCLE website (https://www.radboudumc.nl/Research/
Organisationofresearch/Departments/cdl/SYRCLE/Pages/Protocols.
aspx).
For our ﬁrst research question (does ibogaine reduce addictive
behaviour in animal models of SUDs?) we focused on the two
main behavioural paradigms to measure features of SUDs: the
drug self-administration (SA) and drug-induced conditioned place
preference (CPP) paradigms. The drug SA paradigm measures the
reinforcing effects of drugs of abuse, and—depending on the
schedule of reinforcement used—the pattern, as well as motiva-
tion of animals to self-administer or seek drugs of abuse. The CPP
paradigm measures the rewarding value of drugs of abuse and the
ability of the animals to link this to the context in which they
experience the reward.23 For our second research question (does
ibogaine supplementation to animals cause adverse toxic
effects?), we focused on the effect of ibogaine on motor
functioning, cerebellar cell loss and cardiac rhythm effects, since
tremors, ataxia and cardiac fatalities (due to cardiac arrhythmias)
are the most commonly reported toxic effects of ibogaine in
human case reports.20 For our third research question (does
ibogaine inﬂuence addiction-related neurobiological response in
animal models of SUDs?), we focused on studies reporting on
dopaminergic and serotonergic effects of ibogaine, since these
neurotransmitters have been reported to play a pivotal role in
SUDs and relapse.24,25 In this context, we deﬁned an ‘animal
model of SUD’ with the animals having experienced the same
drug chronically, which means for at least two times.
Search strategy and selection of the papers
We identiﬁed published manuscripts regarding the effects of
ibogaine in animal models for SUDs in Medline via the PubMed
interface, Embase, Psychinfo, CINAHL and Web of Science, until 1
November 2014. To minimise the risk of overlooking any studies,
we applied a broad search strategy using the following ﬁve search
terms:26,27 ‘Ibogaine’, ‘noribogaine’, ‘12-Methoxyibogamine’, ‘NIH-
-10567’ and ‘Endabuse’ (for the complete search strategy see
Supplementary Table 1). Reference lists of the selected papers
were screened by hand for additional relevant papers.
Experimental animal studies were included in the SR if they
fulﬁlled one of the following criteria: (a) the study employs
ibogaine in a drug SA and/or drug-induced CPP paradigm; (b) the
study is about the effect of ibogaine on cerebellar cell structure,
motor functioning or cardiac rhythm; (c) the study is about the
effect of ibogaine on dopaminergic or serotonergic neurotrans-
mission in an animal with chronic drug use. Studies were
excluded: (a) when they appeared to be a duplicate publication,
review, letter or commentary; (b) when no control group was
included in the experiment; (c) ibogaine treatment was combined
with other drugs and (d) when the study was not an animal
in vivo model.
Using Early Review Organizing Software (EROS; Institute of
Clinical Effectiveness and Health Policy, Buenos Aires, Argentina),
each reference was randomly allocated to two independent
reviewers (MB and ML) who screened it for inclusion on the basis
of title and abstract. In case of doubt, the whole publication was
evaluated. Full-text copies of all publications eligible for inclusion
were subsequently assessed by the same two reviewers and
included if they met our pre-speciﬁed inclusion criteria. Disagree-
ments were solved by discussion with a third investigator (CRH).
Study characteristics and data extraction
From the included studies, bibliographic data such as authors,
year of publication, journal of publication and language were
registered. We also extracted data on study design (number of
animals in the experimental and control groups), animal model
characteristics (animal species, strain, age, body weight, and age
at the beginning of the study and gender), intervention
characteristics (description of addiction model, used drug in
addiction model and its dosage regimen, ibogaine dosage
regimen and administration route) and outcome measures. For
our ﬁrst research question (does ibogaine reduce addictive
behaviour in animal models of SUDs?) outcome measures were
SA of a drug (as quantised by number of active/inactive nose
pokes, lever responses or drug infusions) or drug-induced CPP (as
quantised by time spent in one compartment of a two-
compartment chamber) of an animal. For our second research
question (does ibogaine supplementation to animals cause
adverse toxic effects?) outcome measures were occurrence and
severity of motor impairment (including tremors and ataxia as
measured by uphill orientation on, or falling off a tilted platform),
cerebellar cell loss and cardiac toxicity. For our third research
question (does ibogaine inﬂuence addiction-related neurobiolo-
gical response in animal models of SUDs?) outcome measures
were any proxies of dopamine and/or serotonin function in
different brain regions.
If available, raw data or group averages (mean, median or
incidence) were extracted, as well as s.d., s.e. or ranges and
number of animals per group (n). If more than one experiment
was reported on the same outcome measure in a manuscript, the
experiments were only included separately in the analyses when
other animals were used. Multiple experiments on the same group
of animals were pooled. If the number of animals was reported as
a range, the lowest number of animals was included in the
analyses. If data were presented only graphically, we applied
Universal Desktop Ruler software (http://avpsoft.com/products/
udruler/), to come to an adequate estimation of the outcome
measurements. In case of missing outcome measure data, we
contacted the authors for additional information. If no adequate
estimation could be made or data were missing, the results were
excluded from the analyses. If multiple experimental groups were
compared with the same control group, the group size of the
control group was corrected for the number of comparisons made
(n/number of comparisons).
Assessment of methodological quality and risk of bias
The risk of bias was assessed for each of the included studies by
two authors independently (MB and ML) using SYRCLE’s risk of
bias tool.28 A ‘yes’ score indicates low risk of bias; a ‘no’ score
indicates high risk of bias; and a ‘?’ score indicates unknown risk of
bias. In case of disagreement, a third author was consulted (CRH).
Concerning the number of excluded animals, we assumed that
there had been no exclusion if the number of animals per group
mentioned in the Materials and methods section was identical to
the number stated in the Results section or ﬁgure legends.
Reporting of experimental details on animals, methods and
materials is often limited29 and to overcome the problem of
judging too many items as ‘unclear risk of bias’ we added two
items: reporting of any measure of randomisation; and reporting
of any measure of blinding. For these two items, a ‘yes’ score
indicates ‘reported’, and a ‘no’ score indicates ‘unreported’.
Data synthesis and statistical analyses
MA was performed using Comprehensive Meta-Analysis software
(version 2.2, Biostat, Englewood, NJ, USA). For all the continuous
outcome measures, the s.d. was calculated if only the s.e. was
reported (s.d. = s.e. ×√n). In case, data were presented as median
and percentiles, these data were converted to mean and s.d.30 In
the data set on ibogaine toxicology, both continuous and
dichotomous data were reported, which were analysed separately.
When one of the cells to calculate a risk ratio (RR) contained a
zero-value or the risk in either the control or experimental group
was 100%, we added 0.5 to each cell to calculate the RR. Despite
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anticipated heterogeneity, individual effect sizes were pooled
to obtain an overall standardized mean difference (SMD)
for continuous outcome measures and a RR for dichotomous
outcome measures, with their 95% conﬁdence intervals. A random
effects model31 was used, which takes the precision of individual
studies and the variation between studies into account and
weights each study accordingly.
Explorative subgroup analyses were performed for different
dosages of ibogaine, different time frames for the effect, different
animal species, gender and type of drug used, only if at least four
studies were available per subgroup. These subgroups were
speciﬁed in advance and documented in the protocol (www.
syrcle.nl). Because dosing regimens varied considerably among
studies, we also grouped studies into low, medium and high dose
studies, corresponding with 0–40 mg kg− 1, 40–80 mg kg− 1 and
480 mg kg− 1, respectively. Dosages used by humans are typically
between 10 and 25 mg kg− 1 orally.12 When translating these
dosages to animal studies according body surface area32 and
taking into account differences in effects after oral and i.p. dosing
regimens33 they correspond with 40–80 mg kg− 1. Because the
starting point of measurements after the ibogaine supplementa-
tion varied considerably between studies, we grouped these in to
three time frames, corresponding with 0–24 h, 24–72 h and472 h
after ibogaine supplementation, respectively. Since motor impair-
ment is most often reported during the ﬁrst 24 h after ibogaine
administration, this could inﬂuence measurements. It is relevant to
explore the effects beyond the acute phase of 24 h, since human
reports claim ibogaine has a lasting effect for several months even
after a single dose.34 Morphine and heroine (di-acetyl morphine)
were grouped together under opioids since their working
mechanism are almost identical. We assumed that the variance
was comparable within the subgroups; therefore, we assumed a
common among-study variance across subgroups. For subgroup
analyses, we applied a Bonferroni correction for multiple testing
(p* number of comparisons). However, differences between
subgroups should be interpreted with caution and should only
be used for constructing new hypotheses rather than for drawing
ﬁnal conclusions.
Sensitivity analyses and publication bias analyses
We performed sensitivity analyses to assess the robustness of our
ﬁndings, by changing the boundaries of dosage regimen and time
frames. We also assessed whether analysing morphine and heroin
separately would change the results for this group. Furthermore,
we assessed the possibility of publication bias by evaluating
symmetry in the funnel plot for the outcome measure SA,
performing Duval and Tweedie's trim and ﬁll analysis, and Egger's
regression analysis for small study effects. Heterogeneity was
assessed using I2.
RESULTS
Study selection process and search results
Our search yielded 361 records from PubMed, 532 articles from
EMBASE, 107 from Psychinfo, 10 from CHINAHL and 373 of Web of
Science. About 660 articles appeared to be unique (see Figure 1
for a consort ﬂow chart). Ultimately, 30 articles (all in English
language) matched the inclusion criteria (Supplementary Table 2).
These 30 articles contained 32 studies, which were included for
SR (see Supplementary Table 3 for study characteristics). Eleven
studies described the drug SA or CPP paradigms. Nineteen studies
were on ibogaine toxicity. From four of these studies data could
not be retrieved. There were no in vivo studies on the cardiac
effects of ibogaine, which matched our inclusion criteria. Only two
papers reported dopaminergic and/or serotonergic effects of
ibogaine in animals that had chronic contact with drugs. The
remaining 28 studies were analysed in MA. Most comparisons
were conducted in rats (87%), and the remaining in mice. In the
majority of comparisons, male animals were used (73%). Weight of
the animals was reported in 21 studies (70%) and half of the
studies reported the age of the animals. From the behavioural
effect studies, four studies reported on the effect on cocaine use,
four on morphine, one on heroin, one on amphetamine and one
on alcohol use.
Description of characteristics and MA of the effects of ibogaine in
animals
Effect of ibogaine on drug SA. From 8 studies, 29 independent
comparisons about the effect of ibogaine on drug SA could be
included in MA. The data of 10 independent comparisons from 3
studies could not be retrieved for MA.35–37 MA indicates that
ibogaine reduced drug SA (SMD=− 1.54 [− 1.93; − 1.14] n= 29;
I2 = 64%), (Figure 2). In none of the comparisons, ibogaine
enhanced drug SA.
Subgroup analyses revealed a larger reduction of SA in the ﬁrst
24 h after ibogaine dosing (SMD=− 2.42 [− 3.05; − 1.78] n= 25;
I2 = 71%), compared with measurements after this time point (24–
78 h: SMD=− 1.14 [− 1.60;− 0.68] n= 13; I2 = 46%; P = 0.003,
472 h: SMD=− 0.92 [− 1.50; − 0.34] n= 9; I2 = 65%; P= 0.002)
(Figure 3.).
There was no difference in the effect of ibogaine on SA between
other subgroups, with different types of drugs being used
(cocaine, opioids and ethanol), gender or dosing levels. There
was also no difference between these subgroups if we analysed
the prolonged effect of ibogaine on SA (measurements 424 h
after ibogaine dosing) (Table 1). We could not analyse for species
subgroup because the number of comparisons was o4. The
overall in-between study heterogeneity was large (I2 = 64%).
Effect of ibogaine on drug-induced CPP. Fourteen independent
comparisons from 3 studies reported about the effect of ibogaine
on drug-induced CPP, 4 using amphetamine and 10 using
morphine. Ibogaine did not reduce drug-induced CPP (SMD=
− 0.22 [− 0.53; 0.08] n= 14; I2 = 39%; see Figure 4). Subgroup
analyses were not performed for gender, strain and species, as all
comparisons were done with male Sprague–Dawley rats. There
were no differences in effects of ibogaine on drug-induced CPP in
the comparison of subgroups, with different types of drugs being
used (amphetamine and opioids), different time frames of
measurement after ibogaine supplementation and dosing levels
(Supplementary Table 5). There was also no difference between
the subgroups of one cycle of CPP learning or two or more cycles.
The overall in-between study heterogeneity was moderate
(I2 = 39%).
Toxic effects of ibogaine
The effect of ibogaine on motor functioning: Eight studies
reported on toxic effects of ibogaine on motor functioning, from
which three study data could not be retrieved.37–39 From the 5
other studies, 10 independent comparisons with continuous
outcome measures and 6 with dichotomous outcome measures
reported about the effect of ibogaine on motor functioning. Both
the continuous and dichotomous outcome measures showed that
the administration of ibogaine caused motor impairment (con-
tinuous: SMD= 0.82 [0.46; 1.17] n = 10; I2 = 0%, dichotomous:
RR = 6.20 [2.20; 17.44] n= 6; I2 = 15; see Figure 5). All measure-
ments were obtained within 24 h after ibogaine administration. In
all comparisons male animals were used. Eight comparisons used
rats, and the other eight used mice.
There was no difference in the occurrence of motor symptoms
after ibogaine between different dosing regimens (continuous
measurements: o40 mg kg− 1: SMD= 1.11 [0.44; 1.78] n= 5;
I2 = 0%; 40–80 mg kg− 1: SMD=0.61 [0.07; 1.15] n = 4 I2 = 0%;
dichotomous measurements: o40 mg kg− 1: RR = 5.61 [1,15;
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17.44] n= 4; I2 = 46%; see Supplementary Table 6). However,
subgroups on dosages of480 mg kg− 1 were too small to analyse,
as well as the subgroup of medium dosage in the group of
dichotomous measurements. The in-between study heterogeneity
was low for both the continuous and dichotomous outcome
measures (I2 = 0% and 15%, respectively).
The effect of ibogaine on cerebellar cell loss: Eleven studies
reported on toxic effects of ibogaine on cerebellar cell loss. From
the 11 studies, 1 study data could not be retrieved.40 From the 10
other, 28 comparisons reported on the effects of ibogaine
administration on cerebellar degeneration. Indicators of cerebellar
degeneration applied were the Nadler–Evenson method, glial
ﬁbrillary acidic protein immunocytochemical, ﬂuoro-jade or
anti-calbinidin staining or according to immune reactivity with
antibodies against calcium-calmodulin-dependent protein kinase
II (Cam KII). Both the continuous and dichotomous outcome
measures showed that administration of ibogaine causes cere-
bellar cell loss (continuous: SMD=0.78 [0.32; 1.23] n = 13; I2 = 42%,
dichotomous: RR = 2.60 [1.35; 5.01] n = 15; I2 = 0; see Figure 6).
In the group with continuous measurements, six comparisons
applied oral ibogaine administration. In the dichotomous group,
ibogaine was administered i.p. The effect of ibogaine on cerebral
cell loss was only observed in comparisons with i.p. administra-
tion, but not after oral administration (i.p.: SMD= 1.27 [0.87; 1.66]
n= 7; I2 = 4%; oral: SMD=− 0.22 [− 0.89; 0.45] n= 6 I2 = 0%).
There was no effect of gender on the results, nor was there a
difference between mice and rats (analysed in the dichotomous
studies). In the group of continuous measurements, all animals
were rats, and in this group we could not analyse potential
differences between dosing groups because the number of
comparisons was o4. However, in the group with dichotomous
measurements no effect was found in the medium dosing groups
in contrast with the high dosing group (Supplementary Table 7). In
the group with continuous measurements only, cell loss was
observed when measured472 h after ibogaine supplementation.
The overall in-between study heterogeneity was moderate in the
group with continuous measurements (I2 = 42%) and zero in the
group with dichotomous measurements.
The effect of ibogaine on heart rhythm: No studies were found
on cardiovascular effects of ibogaine that matched our inclusion
criteria.
Neuropharmacological effects of ibogaine in animal models of
SUDs. Only two studies matched our inclusion criteria.15,16 These
studies showed that ibogaine treatment lowered drug-induced
dopamine efﬂux in rats, as measured with dialysate levels in the
nucleus accumbens and striatum after chronic cocaine or
morphine use (SMD=− 1.14 [− 2.03; − 0,26] n = 2; I2 = 0%).
Summary of results. See Table 2 for a summary of the results.
Figure 1. Flow chart of the study selection.
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Risk of bias, quality of reporting and publication bias
Of the 30 studies included in this SR, only few applied methods to
avoid bias. Five studies (17%) reported randomisation of
treatment in some way. However, none of these studies
mentioned the methods of randomisation applied. None of the
papers stated that the experiments were blinded, described the
allocation sequence or concealing during the randomisation
process. Measures to reduce performance bias (random housing
and blinding of the caregivers) were reported in only one study.
None of the studies reported that the outcome assessor was
blinded for the allocation of the animals. Only one study reported
random outcome assessment. In 27% of the studies, the baseline
characteristics varied between the control group and experimen-
tal group at the start of the experiment. Most potential sources of
bias had to be scored as unclear risk of bias, as a consequence of
poor reporting (Supplementary Figure 1).
Inspection of the funnel plots suggested some asymmetry due
to an underrepresentation of studies with moderate to low
precision and increased drug SA after ibogaine use. Duval and
Tweedie's trimm and ﬁll analysis for the data set on drug SA
resulted in 4 extra data points of the total of 29 comparisons,
indicating slight overestimation of the summary effect size
(Supplementary Figure 2). Sensitivity analysis revealed that
changing the boundaries of our inclusion criteria and the
classiﬁcation of our subgroups did not alter our results
signiﬁcantly.
DISCUSSION
The current MA on the effect of ibogaine treatment in animal
models of SUDs is, to the best of our knowledge, the ﬁrst of its
kind. Ibogaine was found to reduce SA of cocaine, ethanol and
opioids in animals, but lacked an effect on CPP learning
paradigms. The effect on SA lasted for over 72 h after ibogaine
administration, indicating potentially long-term beneﬁcial effects.
Ibogaine treatment also induced motor impairment during the
ﬁrst 24 h after ibogaine administration, independent of the
dosage used. Dose-dependent cerebellar cell loss was observed
even weeks after ibogaine administration. No animal studies
regarding cardiac toxicity of ibogaine treatment were identiﬁed.
Figure 2. Forest plot of the impact of ibogaine on drug self-administration (SA). A negative outcome means reduction of SA; a positive
outcome means an enhancement. Data are presented as standardized mean differences (SMD) and 95% conﬁdence intervals (CI).
Figure 3. Effect (standard mean difference (SMD)) of ibogaine on
drug self-administration (column, effect size; line, conﬁdence
interval (CI)) as function in three time frames (0–24 h, 24–
72 h,472 h) after ibogaine dosing.
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Table 1. Effects of ibogaine on drug self-administration in different subgroups for all comparisons (blue, n= 29) and for all comparisons 24 h after
ibogaine dosing (green, n= 13)
Upper limit
Abbreviation: SMD, standard mean difference. (Low dose: 0–40 mg kg−1 (not present in 424 h subgroup); Medium dose: 40–80 mg kg− 1; High dose:
480 mg kg− 1). None of the subgroups showed a signiﬁcant difference. Subgroup analyses were conducted when the subgroups contained at least four
comparisons.
Figure 4. Forest plot of the impact of ibogaine on drug-induced conditioned place preference (CPP). A negative outcome means reduction of
CPP; a positive outcome means an enhancement. Data are presented as standardized mean differences (SMD) and 95% coincidence intervals.
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Similarly, studies on the neuropharmacology of ibogaine treat-
ment in animal models of SUDs are limited as well.
The observation that ibogaine reduces SA of cocaine, ethanol
and opioids is consistent with clinical observations in humans and
previous narrative reviews of animal studies.10,12,14,41 Though the
beneﬁcial effects of ibogaine were most prominent in the ﬁrst 24 h
after administration, the beneﬁcial effects lasted for over 72 h. This
is in line with human case reports, describing long-lasting effects
of ibogaine on craving in patients with cocaine and opiate
dependence, for several months.42,43
While ibogaine decreases drug SA, it is not effective in reducing
drug-induced CPP. One difference between the two paradigms is
that CPP measures aspects of Pavlovian conditioning of an animal
experiencing rewarding or salient effects of a substance in a given
context. Pavlovian conditioning is an automatic, involuntarily
reﬂex-like process. The drug SA paradigm, on the other hand,
involves a combination of Pavlovian and operant conditioning. A
cue presented in the test cage signals the availability of the
substance through Pavlovian conditioning, serving as a condi-
tioned reinforcer. In addition, based on both the conditioned
reinforcer and the rewarding effects of the substance itself the
animals are reinforced to press on a lever or to poke into a nose-
poke-hole to obtain the substance. Hence, active behaviour is
required in the drug SA paradigm, which may eventually develop
as a habit. Because of the voluntarily nature of the drug SA
paradigm, this paradigm has greater translational value compared
with the CPP paradigm. It is tempting to speculate that ibogaine
reduces drug SA, reﬂecting an effect on the reinforcing properties
of a substance as measured by operant conditioning, but not
Pavlovian conditioning that is linked to the rewarding effects
of drugs.
We found that ibogaine causes acute motor impairment in
animals, even in low dosages. No studies published results on
whether these effects last over time, although three of the ﬁve
studies described that tremors and ataxia disappeared within
24 h.44–46 This would be consistent with human studies, where
these effects also disappeared within 24 h.47 It is hypothesised
that these effects on motor functioning are caused by ibogaines’
exciting effect on neurons in the inferior olivary nucleus, within
the medulla oblongata. Sustained release of glutamate in neurons
of the olivary nucleus triggered by ibogaine may contribute to
excitotoxic degeneration of cells within the cerebellum.48 Indeed,
high doses of ibogaine were associated with reduced cerebellar
cell counts. It has been suggested that the motor effects of
ibogaine mediate the beneﬁcial effects of ibogaine on drug SA.
However, some studies report an absence of the effect of ibogaine
on water-intake, making this hypothesis less likely.49
We did not encounter animal studies focussing on the effects of
ibogaine on the heart rhythm, matching our inclusion criteria.
However, we found one study showing a decrease in heart rate,
blood pressure and cardiac output in four anaesthetised dogs
receiving 5 mg kg− 1 of ibogaine besides barbital.50 We also found
some animal studies about the cardiovascular effect of taber-
nanthine (an isomer of ibogaine, different in the position of a
methoxyl group) reporting bradycardia and hypotension.51–53
Mash et al.47 reported that no electrocardiographic abnormalities
were seen in 150 patients treated with ibogaine. Notably, in this
study it is unclear which exact methods were used for monitoring.
Other human studies do report potentially life-threatening effects
of ibogaine on heart rhythm.21 Some in vitro studies report an
effect of ibogaine on the human Ether-à-go-go-Related Gene
potassium channel, potentially contributing to prolonged QT
intervals on the electrocardiogram and eventually cardiac
arrhythmias.54 This is particularly relevant, since SUD patients
often use other QT prolonging medication (like methadone and
SSRI’s). Moreover, studies reported bradycardia, hypotension and a
diminished cardiac output after use of an ibogaine-isomer, which
the authors attributed to an effect on calcium mobilisation.50,51
Since cardiac effects of ibogaine could be related to previously
Figure 5. Forest plots for continuous (upper) and dichotomous (lower) effect measures of ibogaine on motor functioning. In the upper plot
(continuous measurements), a negative outcome means enhancement of motor functioning; a positive outcome means an impairment. In this
plot, data are presented as standardized mean differences (SMD) and 95% coincidence intervals. In the lower plot (dichotomous
measurements), an outcome o1 means enhancement of motor functioning; an outcome41 means an impairment of motor functioning. In
this plot, data are presented as risk ratios and 95% coincidence intervals.
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reported fatalities after ibogaine ingestion20 and intoxications,55
there is a great need for animal studies addressing this issue.
Although we conducted a very comprehensive search on the
neuropharmacology of ibogaines’ effects in animal models of
addiction, only two articles matched our inclusion criteria. This
clearly points out that there is a gap of knowledge regarding the
neuropharmacological mechanisms of action of ibogaine in
addiction. Nevertheless, these two studies showed that ibogaine
treatment lowered drug-induced dopamine efﬂux in rats chroni-
cally exposed to drugs. Consistent with the theoretical role of
dopamine in addiction, this could explain why ibogaine is capable
of reducing drug SA in animals and why it may reduce craving and
relapse in patients with SUDs.
Because of the well-established role of speciﬁcally dopaminer-
gic and serotonergic signalling in drug craving, risk-related
decision making, impulse control and relapse in addiction
research,56,57 we decided to explore the pharmacological effects
of ibogaine on these pathways only. However, several other
neurotransmitter systems are relevant in the context of addiction,
particularly for alcohol given its effects on a variety of brain
receptors. Given the limited number of studies identiﬁed in our
search, we conducted retrospective analyses on our search results
to identify studies that investigated (1) other neuropharmacolo-
gical effects of ibogaine and (2) other animal models of substance
use, including single dose studies.
The ﬁrst retrospective analysis identiﬁed one extra article on
cerebral glucose utilisation, indicating ibogaine reduces cerebral
glucose utilisation in morphine-dependent rats.58 This paper did
not report on any effect on speciﬁc neurotransmitter systems. The
second retrospective analysis identiﬁed 14 additional articles
(summarised in Supplementary Table 4). In these articles, 11
studies were about the effect of ibogaine on drug-induced
dopamine efﬂux. Different drugs of abuse were used and
measurements focused on different brain areas. Five studies
showed ibogaine reduced this drug-induced efﬂux of dopamine,
three studies showed an enhancement and three showed no
effect. This lack of a clear direction of effect when animals received
a drug only once is in contrast with our ﬁnding of ibogaines
positive effect in reducing dopamine efﬂux in the animal forced
with more than one drug-suppletion. This could be due to the
limited amount of studies we found, but it would also be
consistent with our ﬁndings that ibogaine affects drug-induced
reinforcement learning (as seen in drug SA) but not Pavlovian
conditioning (as seen in drug-induced CPP).
Studies on the acute effects of ibogaine in animals not exposed
to any drug of abuse show that ibogaine can block N-Methyl-D-
aspartate-type glutamatergic neurotransmission59 and inhibit glial
glutamate re-uptake.60 Other potential neuropharmacological
mechanisms of ibogaine proposed in the literature include
antagonism on the α3β4 nicotinic acetylcholine receptor 61 and
serotonin transporter,62 effects on gene expression including some
transcription factors involved in SUDs (like Fos family protein
(ΔFosB) and cAMP response element binding protein)63 and the
enhancement of glial cell line-derived neurotrophic factor.64,65
However, the exact neuropharmacological mechanism of ibogaine
in the treatment of SUDs remains to be elucidated.
Figure 6. Forest plots for continuous (upper) and dichotomous (lower) effect measures of ibogaine on cerebellar cell loss. In the upper plot
(continuous measurements), a negative outcome means reduction of cerebellar cell loss; a positive outcome means an enhancement. In this
plot, data are presented as standardized mean differences (SMD) and 95% conﬁdence intervals. In the lower plot (dichotomous
measurements), an outcome o1 means that no cerebellar cell loss has occurred, an outcome41 means cerebellar cell loss has occurred. In
this plot, data are presented as risk ratios and 95% coincidence intervals.
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STRENGTHS AND LIMITATIONS OF THE REVIEW
The ﬁndings of this MA should be seen in the light of its strengths
and limitations. A particularly strong point is the systematic and
meta-analytic approach to summarise all available animal
evidence regarding the effects of ibogaine for addiction. Such
an evidence-based approach maximises the changes of successful
translation from bench to bedside.66
However, there are also some limitations to our study. First, the
risk of bias analysis showed poor reporting in most studies
concerning essential methodological details. As a consequence
most items in the risk of bias tool for animal studies28 had to be
scored as unclear risk of bias. It is unclear whether this insufﬁciency
in reporting truly reﬂects hampered methodological rigour, con-
tributing to bias, confounding or skewed ﬁndings.67 Nevertheless, for
both scientiﬁc and ethical reasons methodological reporting of
individual animal studies urgently needs to be improved.22,68,69
Second, this SR/MA contains a relatively low number of studies
and revealed generally moderate to large levels of heterogeneity.
This combination may diminish the certainty in the effect
estimates. Nevertheless, to account for the observed heterogene-
ity we used a random (rather than ﬁxed) effects model in the MA
and conducted subgroup analyses. In addition, one needs to bear
in mind that animal studies are often explorative and hetero-
geneous with respect to species, design and intervention
Table 2. Summary of results
An arrow means an effect was found with a signiﬁcance of Po0.05 or less. Double arrow: effect size42. Direction arrow up: positive effect, direction down:
negative effect. A hyphen means no effect was found (P≥ 0.05). A question mark means insufﬁcient or no data was available.
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protocols and so on, as compared with clinical trials, and
moderate levels of heterogeneity might therefore be expected.
Third, several limitations of the SA and the CPP models of SUDs
should be taken into account. Though the SA model is the best
behavioural paradigm for predicting medication effects for the
treatment of cocaine and opioid dependence,70 and is increas-
ingly used in animal studies on SUDs,71 treatments which are
effective in SA and CPP do not always translate to humans. For
example, not all aspects of SUDs in humans, like socioeconomics,
peer group, and co-morbidity can be modelled in animal models.
In addition, we did not ﬁnd studies on the effect of ibogaine on SA
of other drugs of abuse than opioids, cocaine and ethanol.
Therefore, the current ﬁndings with ibogaine cannot be general-
ised to all SUDs. Yet, studies with 18-Methoxycoronaridine (a
synthetic analogue of ibogaine) and noribogaine (a metabolite of
ibogaine) did also show reduced SA for amphetamine and
nicotine.65,72–76
Finally, no studies took phenotypic animal variation into
account, although this may be highly relevant in the context of
SUDs. For example, some rats are more attracted to conditioned
stimuli predicting reward rather than to the reward (goal) itself.
These so-called sign-trackers are more motivated to self-
administer cocaine,77 and are highly dependent on dopamine.
Dopamine release increases on presentation of a conditioned
stimulus predicting reward in these sign-trackers.78 Since ibogaine
blocks dopamine release in the NAc,15 it is tempting to speculate
that sign-trackers are more responsive to ibogaine than goal-
trackers (attracted to reward delivery). Similarly, trait anxiety and
impulsivity differentially contribute to the liability to SA and CPP,79
and could inﬂuence the efﬁcacy of ibogaine.
RECOMMENDATIONS AND CLINICAL RELEVANCE
Our SR clearly indicates that ibogaine has potentially strong and
long-lasting reducing effects on the amount of drug SA in animals.
However, administration of ibogaine to animals also causes
negative effects, as impaired motor function and cerebellar cell
loss in high dosages given i.p. are observed. In addition, although
we did not ﬁnd clear evidence regarding cardiac toxic effects of
ibogaine, clinical experiences with ibogaine do suggest that
ibogaine can cause potentially fatal cardiac arrhythmias. Given the
great clinical need for effective treatment modalities for addiction,
translational studies on the effects of ibogaine on drug craving
and relapse in humans are urgently needed. To minimise risks of
heart arrhythmias and cerebellar cell loss, we recommend oral and
low dosages of ibogaine to be applied in human studies, only
under close medical monitoring, and after thorough medical
screening.
Last but not least, with this SR, we identiﬁed several gaps of
knowledge in the preclinical literature on the effects of ibogaine.
Animal studies should further unravel the neuropharmacological
mechanisms mediating the effects of ibogaine on substance use.
Further, there is an urgent need for improving methodological
reporting of animal studies, to improve the successful translation
of animal research outcomes into the human clinical setting.
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